MedPage Today broadens its scope

Ivan Oransky
Ivan Oransky

MedPage Today's new VP and global editorial director, Ivan Oransky, has a goal in mind: to make the resource even more top-of-mind among the medical community by broadening and deepening its content and engagement. “We already are global...going more global is a serious undertaking,” says Oransky, who came over from Reuters Health, where he was executive editor.

Oransky, whose experience also includes co-founding the blog Retraction Watch and founding Embargo Watch, as well as stints at Scientific American and the Scientist, tells MM&M that the key to helping MedPage reach its goals is the audience. He plans on enriching MedPage's universe by bringing professionals into the conversation.

This means recruiting and elevating bloggers who are “already out there, but haven't gotten attention.” Oransky says a strong blog network lets professionals “talk among themselves. That's to me, a big sort of gap and a great opportunity.”

But tapping into the everyday voice does not mean moving MedPage to a crowd-sourced news model. Oransky says MedPage will still cover news, but the new voices will mean the site has “more boots on the ground.”

In addition to blogs, Oransky foresees creating a white-list moderated commenting model, which bases its scrutiny of a writer's remarks on past experience: writers who establish themselves as balanced and provocative will be able to post with a limited amount of editorial supervision.

Oransky also anticipates leveraging current assets to a greater degree. He says he wants to do more with contributor Sanjay Gupta, because “he has such a great expertise.” He also envisions newsletters and more relationships with medical societies.

He says he expects to have the beginnings of the new effort in place by mid-fall, as medical conference season hits. The build-out has already started.

Retraction Watch and Embargo Watch will go on. But he stresses that MedPage will come first, saying both Watches must “take a back seat to my real passion, which is of course medical news, healthcare news...building a tremendous community.”
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.